/
Gastroenterology
Celiac Disease
11
Pipeline Programs↗
24
Active Trials↗
14
Companies Involved↗
Celiac Disease is an emerging landscape with 11 programs across 14 companies. The most active players are Forte Biosciences, Inc., Roche, Barinthus Biotherapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
9 of 10 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
77
clinical trials
Completed42 · 55%
Recruiting12 · 16%
Unknown status6 · 8%
Active, not recruiting5 · 6%
Not yet recruiting5 · 6%
Terminated4 · 5%
Other3 · 4%
Clinical Trials
Trial Activity
77 trials
Pathogenic Study of Adult Immune Enteropathies
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·N/A·NCT04280510·200 enrolled
A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
Recruiting·—·Phase 1·NCT07377565·20 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)